ClinicalTrials.gg
RecruitingNCT07358546Updated Nov 5, 2026

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

A Phase 1 interventional study of Efimosfermin alfa in Non-alcoholic Fatty Liver Disease, sponsored by GlaxoSmithKline. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 5, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Planned enrollment
309th of 460
32 · median 56
Started
2026
with 7 others
Phase 1
79 of 547
6 open now
Primary completion
2027-10
later than 49 of 92 live
Registered
541st of 547
by date
Lead sponsor
8 of 547
GlaxoSmithKline

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 309th largest by planned enrollment of the 460 interventional ones that give a count, is one of 8 that started in 2026, is one of 79 in phase 1, reaches primary completion later than 49 of the 92 other live ones, and was the 541st registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.

03

Conditions studied

  • Non-alcoholic Fatty Liver Disease

Keywords

  • efimosfermin alfa
  • Alcohol
  • Hepatic Impairment
  • Steatotic liver disease
  • Metabolic Dysfunction-Associated Steatohepatitis
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 years and 70 years of age inclusive
  • (BMI) within the range 23-40 kilogram per square meter (kg/m\^2)
  • Male or female participants
  • Participant has liver cirrhosis with a grade of hepatic impairment that can be classified as a discrete class. Participants must:

    • Have a clinical diagnosis of liver cirrhosis in the participant's medical history corroborated by previous liver , medical imaging or compatible biochemical profile, and
    • Be classed during Screening as one of the following Child-Pugh classes:

      • Child-Pugh B: Score 7-9 or
      • Child-Pugh C: Score 10-15
  • Chronic (greater than [>] 6 months) HI which is currently stable (no acute episodes of illness within the previous 1 month prior to Screening (Visit 1) due to deterioration in hepatic function). Participants must also remain stable throughout the Screening period. Assessment of the stability of the participant's hepatic function will be determined by the investigator.

Exclusion criteria

Exclusion Criteria:

  • History of extrahepatic disorders possibly related to etiology of cirrhosis.
  • History of cryoglobulinemia.
  • Participants with Grade 3 ascites or ascites.
  • Participants with refractory encephalopathy or significant central nervous system disease
  • History of gastric or esophageal variceal bleeding within the past 6 months and for which varices have not been adequately treated with medication and/or surgical procedures.
  • Other primary causes of liver disease. Steatotic liver disease must be the primary cause of liver disease.
  • abnormalities affecting physical health in medical history, or on physical examination, that could interfere with or for which treatment could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this study.
  • Current, or history of known hepatocellular carcinoma (HCC).
  • Participants with transjugular intrahepatic portosystemic shunt (TIPS) placement.
  • Presence of hepatopulmonary or hepatorenal syndrome.
  • Presence of primarily cholestatic liver diseases.
  • Evidence of symptomatic or complicated cholecystitis.
  • History of pancreatic injury, pancreatitis, or other pancreatic disease.
  • History of liver transplantation, or active on the liver transplant waiting list.
  • Participants with signs of active infection
  • History of adrenal gland disease or using treatment that affects the hypothalamic-pituitary-adrenal axis.
  • History of significant bone disease such as osteoporosis
  • Psychosocial features that, in the opinion of the investigator, increase the likelihood of loss to follow-up.
  • History or presence of drug abuse.
  • Use of other drugs at the time of screening, or within 5 half-lives or 30 days prior to study intervention, whichever was longer; or longer if required by local regulations
  • Have previously taken efimosfermin alfa
  • Participants with (ALT) value >3 times (x) (ULN)
  • Participants with Aspartate aminotransferase (AST) value >=300 Units/Liter.
  • Participants with estimated (eGFR) (Chronic Kidney Disease Epidemiology [CKD-Epi] 2021) \<45 milliliter/minute/1.73 square meter (mL/min/1.73m\^2).
  • Average of triplicate corrected for heart rate using Fridericia formula (QTcF) >480 milliseconds (msec) (for male and female participants) at Screening
  • For participants in the MASH with alcohol category, significant risk of withdrawal symptoms.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Efimosfermin alfa in participants with moderate hepatic impairment due to MASH without alcohol

    All participants will receive efimosfermin alfa. Participants will have moderate hepatic impairment (Child-Pugh B) due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) with typical alcohol consumption threshold in the 3 months prior to Screening of less than (\<) 5 standard drinks on any day and \<15 standard drinks per week for men; or \<4 standard drinks on any day and \<8 standard drinks per week for women.

    Drug: Efimosfermin alfa

  • Experimental
    Efimosfermin alfa in participants with moderate hepatic impairment due to MASH with alcohol

    All participants will receive efimosfermin alfa. Participants will have moderate hepatic impairment (Child-Pugh B) due to MASH with typical alcohol consumption threshold in the 3 months prior to Screening of greater than or equal to (\>=) 5 standard drinks per day or \>=15 standard drinks per week for men; or \>= 4 standard drinks per day or \>=8 or more drinks per week for women.

    Drug: Efimosfermin alfa

  • Experimental
    Efimosfermin alfa in severe hepatic impairment participants due to MASH regardless of alcohol use

    All participants will receive efimosfermin alfa. Participants will have severe hepatic impairment (Child-Pugh C) due to MASH with any typical daily alcohol consumption.

    Drug: Efimosfermin alfa

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the serum drug concentration versus time curve from time zero to infinity (AUC[0-inf]) of efimosfermin alfa

    Time frame: Up to 90 Days

  2. Maximum observed serum drug concentration (Cmax) of efimosfermin alfa

    Time frame: Up to 90 Days

Secondary outcomes

  1. Number of participants with Adverse Events (AEs), treatment related AEs and serious adverse events (SAEs)

    Time frame: Up to 90 Days

  2. Number of participants with clinically significant changes in hematology, chemistry, and urinalysis parameters

    Time frame: Up to 90 Days

  3. Number of participants with clinically significant changes in Vital signs and 12-lead electrocardiogram (ECG) findings

    Time frame: Up to 90 Days

  4. Area under the serum drug concentration versus time curve from time zero to the time of the last quantifiable concentration (AUC[0-t]) of efimosfermin alfa

    Time frame: Up to 90 Days

  5. Time to maximum observed serum drug concentration (Tmax) of efimosfermin alfa

    Time frame: Up to 90 Days

  6. Apparent terminal phase half-life (t1/2) of efimosfermin alfa

    Time frame: Up to 90 Days

  7. Time prior to the first measurable (non-zero) serum concentration (Tlag) of efimosfermin alfa

    Time frame: Up to 90 Days

  8. Apparent clearance (CL/F) of efimosfermin alfa

    Time frame: Up to 90 days

  9. Apparent terminal phase volume of distribution (Vz/F) of efimosfermin alfa

    Time frame: Up to 90 days

  10. Terminal elimination rate constant (Lambda z) of efimosfermin alfa

    Time frame: Up to 90 days

07

Study locations

5 of 5 sites recruiting
  • GSK Investigational Site
    Rialto, California 92377, United States
    Recruiting
  • GSK Investigational Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    Tampa, Florida 33603, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77079, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78215, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2027, 19 months after the start.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 19 months is above that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Jan 22, 2026
StartActual
Mar 13, 2026
Primary completionEst.
Oct 13, 2027
CompletionEst.
Oct 13, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • GSK Investigational Site · Miami Lakes, United States
  • GSK Investigational Site · Houston, United States
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    2 sites added
    Show 2 added (2 United States)
    • GSK Investigational Site · Miami Lakes, United States
    • GSK Investigational Site · Houston, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07358546
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Mar 13, 2026
Primary completion
Oct 13, 2027 (estimated)
Completion
Oct 13, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efimosfermin alfa

Start the discussion